Used in research for the treatment of certain cancers, particularly non-small cell lung cancer (NSCLC) with specific EGFR mutations. It acts as a tyrosine kinase inhibitor, blocking signals that promote tumor growth. Shows activity against both common and resistant forms of EGFR, including T790M mutation, making it a candidate for patients who have progressed on earlier-generation therapies. Investigated in clinical trials to evaluate efficacy, safety, and optimal dosing in advanced or metastatic settings.